Follicular Lymphoma with Late First Relapse or Progression (>24 Months) and High Tumor Burden
This clinical scenario addresses patients with follicular lymphoma who experience a first relapse or progression more than 24 months after the start of initial treatment and whose disease burden is high enough to require active treatment.
Clinical Scenario
The patient presents with follicular lymphoma at late first relapse or progression — defined as occurring more than 24 months from the start of treatment — with a high tumor burden that necessitates a therapeutic intervention.
Treatment Approach (Partial Overview)
Management centres on rescue therapy using a regimen that differs from what was used previously, anchored by an anti-CD20 monoclonal antibody. The full evidence-based protocol — including all recommended regimens, sequencing, and considerations for maintenance — is available below.
Treatment Goal
Achievement of at least a partial response with rescue treatment.
References
DOI: 10.3390/cancers18030395
- For patients treated with induction immunochemotherapy who experience a first relapse/late progression requiring treatment (high tumor burden), the following are recommended:
- It is recommended to use a regimen different from that used in the first or previous lines, ideally without cross-resistance or with a distinct mechanism of action (1C).
- Rescue therapy should include an anti-CD20 monoclonal antibody, rituximab or obinutuzumab (1B).
- Similarly to early relapse, the most commonly used rescue immunochemotherapy regimens are R-CHOP and R-B.
- R2 is an increasingly utilized option and may serve as an alternative rescue option with a different mechanism of action if immunochemotherapy was used previously (1B).
- Rituximab monotherapy (2A).
- Maintenance with rituximab (every 3 months for a maximum 2 years) if at least a partial response is achieved with rescue treatment (1B).
View source ↗